Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma.
about
New molecular targets in mantle cell lymphomaDesigned Inhibitors of Insulin-Degrading Enzyme Regulate the Catabolism and Activity of InsulinHistone acetyltransferases and histone deacetylases in B- and T-cell development, physiology and malignancyPhase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphomaPhase I and pharmacokinetic study of the oral histone deacetylase inhibitor vorinostat in Japanese patients with relapsed or refractory cutaneous T-cell lymphoma.A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphomaEpigenetic mechanisms underlying diet-sourced compounds in the prevention and treatment of gastrointestinal cancerTargetome profiling and functional genetics implicate miR-618 in lymphomagenesisThe clinical development of histone deacetylase inhibitors as targeted anticancer drugs.Role of CAAT/enhancer binding protein homologous protein in panobinostat-mediated potentiation of bortezomib-induced lethal endoplasmic reticulum stress in mantle cell lymphoma cells.Schwann cell autophagy induced by SAHA, 17-AAG, or clonazepam can reduce bortezomib-induced peripheral neuropathyTargeting histone deacetyalses in the treatment of B- and T-cell malignancies.Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy.Classical Hodgkin's lymphoma shows epigenetic features of abortive plasma cell differentiation.Molecular targeted approaches in mantle cell lymphoma.Vorinostat approved in Japan for treatment of cutaneous T-cell lymphomas: status and prospects.A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517.Phase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomasManagement of indolent lymphoma: where are we now and where are we going.Histone deacetylase inhibition: an important mechanism in the treatment of lymphoma.The effects of a histone deacetylase inhibitor on biological behavior of diffuse large B-cell lymphoma cell lines and insights into the underlying mechanisms.Gene mutations and actionable genetic lesions in mantle cell lymphoma.Investigational histone deacetylase inhibitors for non-Hodgkin lymphomas.Current status of targeted therapies for mantle cell lymphoma.Targeting histone deacetylases: development of vorinostat for the treatment of cancer.Toxicological and metabolic considerations for histone deacetylase inhibitors.Clinical pharmacology profile of vorinostat, a histone deacetylase inhibitor.Targeted therapy of epigenomic regulatory mechanisms controlling the epithelial to mesenchymal transition during tumor progression.Overview of Histone Deacetylase Inhibitors in Haematological Malignancies.Suppressive effect of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) on hepatitis C virus replication.Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor/retinoid X receptor activation by histone deacetylase inhibition.CG0006, a novel histone deacetylase inhibitor, induces breast cancer cell death via histone-acetylation and chaperone-disrupting pathways independent of ER status.A novel approach to detect resistance mechanisms reveals FGR as a factor mediating HDAC inhibitor SAHA resistance in B-cell lymphoma.A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma.
P2860
Q26821766-E00663CE-4A78-4F4F-91A3-D841B530E38DQ27661904-211B447A-107B-4886-AFA0-8BAC6940B234Q28082536-A8EA7D7C-4848-4C1E-B44A-20124A9E14A9Q33394023-5E5B1B28-3D8C-4274-B62B-ACF276C821A5Q33400756-0DD7C240-8882-4896-A757-5D6FBA4328FEQ33413857-287DC87E-27D9-44B5-ABA5-0E17C8ED9429Q33587441-E9B55695-FA37-464C-A9E4-F498BA9DCBA5Q33779176-2235071D-468C-4EFD-84D0-4583E0C96788Q33829390-5FCA447C-B943-497E-9521-874462705B54Q34168461-486BFCD4-8BD1-4191-AABC-710291251678Q34344053-2C2393A9-CC2D-4C09-BC47-2685A69D76F3Q34414452-033EBDA1-D7FC-428A-8999-C8F4C74C57E0Q34488424-CC88463E-6B8C-4331-99EB-AF8D8710AD21Q35018530-62D2692D-76E4-484E-AD06-C166ACEA9EF0Q35127368-1284C0AC-29F3-4127-B7DB-CDC3CFA3C4C4Q35939690-B83E98E0-7EBF-443F-A54D-81A22FFB4135Q36337623-05805D7D-8691-4223-8DC1-A5FD40480698Q36703448-4B4FCFCA-47FE-4924-B4B1-F62476161969Q36784860-741B91EA-156D-4303-A01A-147F93D9EE72Q36814349-688EDF27-D184-41E9-8611-42AE5AD62B53Q36926692-6F89FB8B-922E-46AB-ADE1-DABCB58F3703Q37629080-9A81ABBD-3307-4412-9945-273C1C22E6F5Q37774667-AD8359DC-DD9D-4E73-ACB0-91EC49A30D6AQ37956405-65B8A705-4B23-4390-AA3A-7D4CA5A70D1AQ37961738-251D9453-BB51-4936-987B-A95EFF009104Q38071321-6BF8A913-860D-4298-861C-63C663A31592Q38118900-A3744B43-E726-411B-A626-398BF7F41CC3Q38212160-06C557F5-007A-47E9-9BE2-D43B4BC6BA8DQ38974433-81037F20-6328-4242-AA73-47C9D70DDD80Q39177306-CEC95686-A8AE-48A9-AC2D-240883281C34Q39253408-486DD7DC-5649-4F49-9372-F682AEFD1C46Q39616031-D75ABD8C-D261-4576-ADD2-433AC2FAFF4CQ40690632-1711BA7C-2A26-480D-90C6-F935FEA18CF5Q45051052-225FB4F8-DC50-42B2-B95C-0FCA0F026DC3
P2860
Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma.
description
2009 nî lūn-bûn
@nan
2009 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Potential efficacy of the oral ...... ular and mantle cell lymphoma.
@ast
Potential efficacy of the oral ...... ular and mantle cell lymphoma.
@en
type
label
Potential efficacy of the oral ...... ular and mantle cell lymphoma.
@ast
Potential efficacy of the oral ...... ular and mantle cell lymphoma.
@en
prefLabel
Potential efficacy of the oral ...... ular and mantle cell lymphoma.
@ast
Potential efficacy of the oral ...... ular and mantle cell lymphoma.
@en
P2093
P1433
P1476
Potential efficacy of the oral ...... ular and mantle cell lymphoma.
@en
P2093
Akiko Miyagi-Maesima
Harumi Kato
Hiroki Yokoyama
Justin L Ricker
Kensei Tobinai
Satoshi Yamasaki
Takashi Watanabe
Tetsuya Otsuki
Yasuo Morishima
Yoshihiro Matsuno
P304
P356
10.1111/J.1349-7006.2009.01360.X
P577
2009-09-10T00:00:00Z